Sponsor hub
Celgene clinical trial failures
Review 73 stopped clinical trials from Celgene, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 9 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OTHER/UNKNOWN
- 48
- OPERATIONAL
- 15
- SAFETY
- 5
- EFFICACY/FUTILITY
- 4
- REGULATORY
- 1
Notable sponsors
- Celgene
- 73
Related phases
- Phase I
- 44
- Phase II
- 17
- Phase III
- 12
Crawlable stopped-trial records
Open ExploreShowing up to 73 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase III Crohn Disease trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase III Crohn Disease trial by Celgene. Stop reason: SAFETY.
The study has terminated due to non-safety reasons; Business Objectives have changed.
Phase III Crohn Disease trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Leukemia, Myeloid, Acute trial by Celgene. Stop reason: OTHER/UNKNOWN.
Efficacy endpoint met; however, overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population
Phase III Multiple Sclerosis trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objective has changed
Phase I Leukemia, Myeloid, Acute trial by Celgene. Stop reason: EFFICACY/FUTILITY.
Trial terminated because of lack of efficacy in the short term acute phase.
Phase I Leukemia, Myeloid trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Lymphoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase I Lymphoma, Non-Hodgkin trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Change in business priorities.
Phase III Primary Myelofibrosis trial by Celgene. Stop reason: OPERATIONAL.
Slow accrual.
Phase I Lymphoma, Non-Hodgkin trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase I Lymphoma, Non-Hodgkin trial by Celgene. Stop reason: OPERATIONAL.
Business objectives have changed
Phase I Lymphoma, Non-Hodgkin trial by Celgene. Stop reason: OTHER/UNKNOWN.
Replaced it with another clinical trial.
Phase I Neoplasms trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase I Multiple Myeloma trial by Celgene. Stop reason: OPERATIONAL.
Slow accrual
Phase I Precursor Cell Lymphoblastic Leukemia-Lymphoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Absence of significant therapeutic benefit over existing therapies
Phase I Glioblastoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Multiple Myeloma trial by Celgene. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy
Phase I Astrocytoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase I Leukemia, Myeloid, Acute trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase III Multiple Myeloma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Non Small Cell Lung Cancer trial by Celgene. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy
Phase II Spondylitis, Ankylosing trial by Celgene. Stop reason: SAFETY.
The study has been terminated due to Non-Safety reasons because of lack of efficacy in the short-term acute phase.
Phase I Lymphoma, Large B-Cell, Diffuse trial by Celgene. Stop reason: OTHER/UNKNOWN.
Replaced with another clinical trial.
Phase I Healthy Volunteers trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives changed.
Phase II Scleroderma, Systemic trial by Celgene. Stop reason: OPERATIONAL.
Enrollment was stopped early (see limitations and caveats section).
Phase II Idiopathic Pulmonary Fibrosis trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase II Beta Thalassemia Major trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase II Non-alcoholic Fatty Liver Disease trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Leukemia, Myeloid trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed.
Phase I Carcinoma, Squamous Cell trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase II Multiple Myeloma trial by Celgene. Stop reason: REGULATORY.
Health Authority request due to class effect
Phase I Lymphoma, B-Cell trial by Celgene. Stop reason: OTHER/UNKNOWN.
Business objectives have changed
Phase I Healthy Volunteers trial by Celgene. Stop reason: EFFICACY/FUTILITY.
Did not meet progression criteria
Phase III Carcinoma, Non-Small-Cell Lung trial by Celgene. Stop reason: OTHER/UNKNOWN.
BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound, pending the acquisition of Celgene by Bristol Myers Squibb
Phase I Myelodysplastic Syndrome trial by Celgene. Stop reason: SAFETY.
The compound has a benign safety profile with short-term use, clinically sig efficacy responses have not been demonstrated, or if so, have not been sustained.
Phase I Stage IV (Metastatic) Breast Cancer trial by Celgene. Stop reason: OTHER/UNKNOWN.
Unable to determine the optimum tolerated dose
Phase II Multiple Myeloma trial by Celgene. Stop reason: SAFETY.
There was a change in the Sponsor's research strategy; safety concerns were not a factor.
Phase II Hemodialysis Graft Dysfunction trial by Celgene. Stop reason: OPERATIONAL.
Terminated due to pipeline prioritization
Phase II T-cell Non-Hodgkin's Lymphoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Decision not to pursue as single agent in the study population.
Phase I Renal Cell Carcinoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.
Phase II Metastatic Breast Cancer trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Breast Neoplasms trial by Celgene. Stop reason: OTHER/UNKNOWN.
sufficient mature data to complete a final analysis
Phase I Carcinoma, Small Cell trial by Celgene. Stop reason: OPERATIONAL.
This study was terminated for administrative reasons.
Phase II Idiopathic Pulmonary Fibrosis trial by Celgene. Stop reason: OTHER/UNKNOWN.
The benefit/ risk profile does not support continuation of this study.
Phase III Mantle Cell Lymphoma trial by Celgene. Stop reason: OPERATIONAL.
Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.
Phase II Soft Tissue Sarcoma trial by Celgene. Stop reason: OPERATIONAL.
Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety.
Phase II Discoid Lupus trial by Celgene. Stop reason: SAFETY.
The benefit/risk profile does not support continuation of this study.
Phase I Neoplasm Metastasis trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Parapsoriasis trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Advanced Solid Tumors trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Metastatic Breast Cancer trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Sarcoidosis trial by Celgene. Stop reason: OPERATIONAL.
Administrative
Phase I Pancreatic Neoplasms trial by Celgene. Stop reason: OTHER/UNKNOWN.
Study population more infrequent than estimated. No study-related safety issues and no safety concerns were identified for the study.
Phase I Squamous Cell Carcinoma of the Head and Neck trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Fallopian Tube Neoplasms trial by Celgene. Stop reason: OTHER/UNKNOWN.
MTD not determined
Phase I Low Grade B Cell Lymphoma trial by Celgene. Stop reason: OPERATIONAL.
The study was stopped due to slow rate of recruitment.
Phase III Crohn Disease trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Crohn's Disease trial by Celgene. Stop reason: OPERATIONAL.
Study terminated by Sponsor following a recommendation from external DMC based on lack of emerging benefit; there were no new emergent safety findings
Phase II Breast Neoplasms trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Leukemia, Myeloid, Acute trial by Celgene. Stop reason: OTHER/UNKNOWN.
Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion
Phase II Crohn's Disease trial by Celgene. Stop reason: OPERATIONAL.
Study terminated by Sponsor following a recommendation from external DMC to terminate the ongoing Phase 3 CD studies; there were no new emergent safety findings
Phase I Solid Tumor trial by Celgene. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Multiple Myeloma trial by Celgene. Stop reason: OPERATIONAL.
The study was terminated due to poor feasibility and lack of interest at the participating sites.
Phase III Crohn Disease trial by Celgene. Stop reason: OPERATIONAL.
Sponsor decision not to start trial
Phase I Precursor Cell Lymphoblastic Leukemia-Lymphoma trial by Celgene. Stop reason: OTHER/UNKNOWN.
Development of JCAR015 has been discontinued. No subjects were enrolled/treated under protocol JCAR015-ALL-001
Phase I Carcinoma, Hepatocellular trial by Celgene. Stop reason: OPERATIONAL.
Slow enrollment and business decision. No safety concerns were identified for the study drugs.